Immunity Bio, Inc. IBRX
We take great care to ensure that the data presented and summarized in this overview for ImmunityBio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IBRX
View all-
Vanguard Group Inc Valley Forge, PA16.9MShares$82.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$55.7 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$42.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$18.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$11 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.07MShares$10.1 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.55MShares$7.56 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.54MShares$7.54 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.29MShares$6.29 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA1.27MShares$6.18 Million0.0% of portfolio
Latest Institutional Activity in IBRX
Top Purchases
Top Sells
About IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Insider Transactions at IBRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 05
2024
|
Richard Adcock CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
43,165
-15.08%
|
$172,660
$4.04 P/Share
|
|
Feb 05
2024
|
Richard Adcock CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
83,334
+22.54%
|
-
|
|
Jan 31
2024
|
Barry J. Simon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
22,094
-0.7%
|
$66,282
$3.36 P/Share
|
|
Jan 31
2024
|
Barry J. Simon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
57,200
+1.79%
|
-
|
|
Jan 31
2024
|
Regan J Lauer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,470
-12.49%
|
$40,410
$3.36 P/Share
|
|
Jan 31
2024
|
Regan J Lauer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,872
+23.37%
|
-
|
|
Jan 31
2024
|
David C. Sachs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,835
-12.62%
|
$80,505
$3.36 P/Share
|
|
Jan 31
2024
|
David C. Sachs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,745
+24.96%
|
-
|
|
Dec 31
2023
|
Richard Adcock CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
17,096
-7.77%
|
$85,480
$5.02 P/Share
|
|
Dec 31
2023
|
Richard Adcock CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
34,483
+13.55%
|
-
|
|
Dec 31
2023
|
David C. Sachs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,511
-6.9%
|
$52,555
$5.02 P/Share
|
|
Dec 31
2023
|
David C. Sachs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,397
+16.63%
|
-
|
|
Dec 15
2023
|
Regan J Lauer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,030
+21.91%
|
-
|
|
Sep 11
2023
|
Patrick Soon Shiong Director |
BUY
Other acquisition or disposition
|
Indirect |
209,291,936
+49.99%
|
$209,291,936
$1.29 P/Share
|
|
Sep 01
2023
|
Regan J Lauer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,872
+37.88%
|
-
|
|
Sep 01
2023
|
David C. Sachs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,744
+36.7%
|
-
|
|
Sep 01
2023
|
Barry J. Simon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
57,199
+1.82%
|
-
|
|
Jun 15
2023
|
Regan J Lauer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,030
+50.0%
|
-
|
|
Jun 05
2023
|
Michael D Blaszyk Director |
BUY
Open market or private purchase
|
Indirect |
71,915
+30.29%
|
$143,830
$2.75 P/Share
|
|
Jun 02
2023
|
John Owen Brennan Director |
BUY
Open market or private purchase
|
Direct |
25,000
+39.52%
|
$50,000
$2.81 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 330K shares |
|---|
| Payment of exercise price or tax liability | 133K shares |
|---|